Synthesis and X-ray crystal structure of the dirhenium complex Re2(i-C3H7COO)4Cl2 and its interactions with the DNA purine nucleobases

Shtemenko, A. V.; Chifotides, Helen T.; Yegorova, Dina E.; Штеменко, Н. И.; Dunbar, Kim R.

doi:10.1016/j.jinorgbio.2015.06.012

Cited by 16 publications

(11 citation statements)

References 60 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The packing of radical cations in the crystal and the properties of radical cation salts depend substantially on the type of anions involved (Mori et al, 1999;Mori, 1999). Labile equatorial chloride or bromide groups around the Re 2 6+ cluster unit are the reactive centres in interactions with other chemical compounds and biological macromolecules (Shtemenko et al, 2013(Shtemenko et al, , 2015. Only one radical cation salt containing a rhenium-rhenium quadruple bond has been described so far {(ET) 2 [Re 2 Cl 8 ] [ET = bis-(ethylenedithio)tetrathiafulvalene]; Reinheimer et al, 2008}. In this context, we present the synthesis and crystal structure of a new radical cation salt of ET with the dirhenium(III) anion [Re 2 Br 6 (CH 3 COO)] À .…”

Section: Chemical Contextmentioning

confidence: 99%

Crystal structure of bis(ethylenedithio)tetrathiafulvalenium μ₂-acetato-bis[tribromidorhenate(III)] 1,1,2-trichloroethane hemisolvate

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Chemical Contextmentioning

confidence: 99%

Crystal structure of bis(ethylenedithio)tetrathiafulvalenium μ₂-acetato-bis[tribromidorhenate(III)] 1,1,2-trichloroethane hemisolvate

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our earlier studies have shown that combination therapy using cisPt and dirhenium(III) clusters in reduction of tumors in tumor-bearing animals was very effective (Shtemenko et al, 2009(Shtemenko et al, , 2013(Shtemenko et al, , 2015Shtemenko, Shtemenko, 2017). Thus, it was not a surprising thing, that a substation effect was observed in groups T8+[I]sl and T8+[I]nl+cisPt, where cisplatin and I were introduced together (Fig.…”

Section: Animal Studies Anticancer Activity Of I and I+cispt In Vivomentioning

confidence: 92%

Dirhenium(III) complex with beta-alanine ligand: anticancer, antioxidant and DNA-binding properties

2020

The Journal of v. N. Karazin Kharkiv National University, Series "Biology"

View full text Add to dashboard Cite

Earlier we have shown that dirhenium(III) dicarboxylate complex with γ-aminobutyric acid possessed higher antitumor activity, than those of the previously investigated alkylcarboxylates, also may act as a modulator of cisplatin mechanism of action and as a stabilizer of red blood cells in tumor-bearing organisms. Thus, the task of the work was to investigate anticancer activity of the complex cis-[Re2(β-Ala)2Cl6] (I) in the model of tumor growth in vivo and to realize if the amino acid residue influences the DNA-binding activity of the amino acid derivatives of the cluster rhenium(III) compounds. Antitumor properties of the complex I were studied in the model of tumor growth with the use of Wistar rats inoculated by tumor carcinoma Guerink cells. The introduction of the compound alone in free and liposomal forms inhibited the tumor growth by 36 % and 45 % correspondingly, that is more than for dirhenium(III) clusters with alkyl ligands. The combined introduction of I and cisplatin had a significant impact on the tumor growth and showed the disappearance of the tumors in most of the animals. No considerable differences were found between introduction of liposomal and free form of I. The electronic absorption spectra of Calf Thymus DNA (CT-DNA) exhibit hyperchromism in the presence of increasing amounts of I. The DNA band at ~ 260 nm arises from the π-π* transitions of the nucleic acid bases and changes in the intensity and slight wavelength shifts of this characteristic band reflect the corresponding structural modifications of the DNA, which include changes in stacking, disruption of the hydrogen bonds between complementary strands, covalent binding of the DNA bases, intercalation of aromatic rings and others. The binding constant Kb(I) = 2.43 × 103 M-1 to CT-DNA was obtained that was lower than the values reported for the classical DNA intercalators and compares well with the magnitude of the binding constants for other complexes of dirhenium(III); titration of СT-DNA with cisPt and hydrogen peroxide also leads to a hypochromic effect, weak at low concentrations and more significant at high concentrations of I; the DNA binding constants increased in several times when using H2O2 or cisplatin that confirms a mechanism for redox activation of interaction of I with DNA in a cancer cell. The obtained results demonstrate the possibility of application of the amino acid derivatives of dirhenium(III) clusters in antitumor therapy.

show abstract

“…In our research, we studied the cluster compound dichlorotetra-μ-isobutyratodirhenium(ІІІ) Re 2 (i-C 3 H 7 COO) 4 Cl 2 -(i) synthesized in the Ukrainian State University of Chemical Technology, Dnipro [13]. Nanoliposome [i] nl forms of i and the Re-Pt system with 4:1 ratio of the components inside lipid [i+cPt (4:1)] nl, [i+cPt (4:1)] np were prepared ibid according to [14].…”

Section: Methodsmentioning

confidence: 99%

The concentration of ceruloplasmin in blood of tumor-bearing rats after administration of a dirhenium(III) compound and cisplatin

Hrabovska¹,

Shamelashvili²,

Shtemenko³

et al. 2019

Ukr.Biochem.J

View full text Add to dashboard Cite

Contemporary investigations of mechanisms of resistance to platinides showed the key role of copper metabolism in cancer patients and proposed possible methods to attenuate the resistance by modulation of copper transporting mechanisms. In this vein, investigation of ceruloplasmin (Cp) levels -the main coppercontaining protein in blood, in experiments with tumor-containing animals upon cytostatics administration is topical and has great importance. the concentration of Cp was measured in the serum of tumor-bearing rats with ordinary (t8) and resistant to cisplatin (t8*) Guerin's carcinoma upon administration of cisplatin and quadruple bonding dirhenium(III) compound dichlorotetra-μ-isobutyratodirhenium(ІІІ) (I) in different medicamental forms. It was shown that development of tumor in t8 group led to increasing of concentration of Cp in 3.7 times and in T8* group -more than in 8 times in comparison to control, confirming the essential role of Cp in the formation of resistance phenomenon. administration of cisplatin together with I led to effective inhibition of tumor in groups with t8 and t8*, indicating decreased resistance in the group t8*. Greater reduction of Cp levels was observed in the groups with t8* upon administration of the rhenium-plati num antitumor system, than in groups with t8, that underlines the importance of further investigations of the dirhenium(III) compounds in the resistance to cytostatics cancer models. Some mechanisms concerning the regulation of copper homeostasis and properties of nano-composites are discussed. k e y w o r d s: ceruloplasmin, cluster rhenium(III) compound, Guerin's carcinoma, resistance to cisplatin.

show abstract

Synthesis and X-ray crystal structure of the dirhenium complex Re2(i-C3H7COO)4Cl2 and its interactions with the DNA purine nucleobases

Cited by 16 publications

References 60 publications

Crystal structure of bis(ethylenedithio)tetrathiafulvalenium μ₂-acetato-bis[tribromidorhenate(III)] 1,1,2-trichloroethane hemisolvate

Crystal structure of bis(ethylenedithio)tetrathiafulvalenium μ₂-acetato-bis[tribromidorhenate(III)] 1,1,2-trichloroethane hemisolvate

Dirhenium(III) complex with beta-alanine ligand: anticancer, antioxidant and DNA-binding properties

The concentration of ceruloplasmin in blood of tumor-bearing rats after administration of a dirhenium(III) compound and cisplatin

Contact Info

Product

Resources

About

Synthesis and X-ray crystal structure of the dirhenium complex Re2(i-C3H7COO)4Cl2 and its interactions with the DNA purine nucleobases

Cited by 16 publications

References 60 publications

Crystal structure of bis(ethylenedithio)tetrathiafulvalenium μ2-acetato-bis[tribromidorhenate(III)] 1,1,2-trichloroethane hemisolvate

Crystal structure of bis(ethylenedithio)tetrathiafulvalenium μ2-acetato-bis[tribromidorhenate(III)] 1,1,2-trichloroethane hemisolvate

Dirhenium(III) complex with beta-alanine ligand: anticancer, antioxidant and DNA-binding properties

The concentration of ceruloplasmin in blood of tumor-bearing rats after administration of a dirhenium(III) compound and cisplatin

Contact Info

Product

Resources

About

Crystal structure of bis(ethylenedithio)tetrathiafulvalenium μ₂-acetato-bis[tribromidorhenate(III)] 1,1,2-trichloroethane hemisolvate

Crystal structure of bis(ethylenedithio)tetrathiafulvalenium μ₂-acetato-bis[tribromidorhenate(III)] 1,1,2-trichloroethane hemisolvate